Affiliation:
1. Republican Clinical Oncology Center; Bashkir State Medical University
2. Republican Clinical Oncology Center
3. Bashkir State Medical University
4. Center PET-Technology LLC
Abstract
According to GLOBOCAN, there were about 18 million new cases of cancer and 9.6 million deaths from malignancies worldwide in 2018. Renal cell carcinoma is a malignant tumor characterized by the loss of the VHL gene, which leads to increased angiogenesis. The potential of immuno-oncology and anti-angiogenic drugs has significantly improved outcomes for patients with metastatic renal cell carcinoma. The phase III CheckMate 9ER study compared the efficacy and safety of nivolumab plus cabozantinib versus sunitinib in the first-line treatment of patients with metastatic clear cell renal cell carcinoma. The advantages of nivolumab plus cabozantinib over sunitinib in terms of progression-free survival, overall survival, and objective response rate were generally similar across subgroups based on IMDC risk, PD-L1 expression, and the presence or absence of bone metastases. We present a case report of metastatic renal cell carcinoma. The patient has been on cabozantinib plus nivolumab therapy for 12 months, with a partial response achieved. Treatment was well tolerated; the profile of adverse events was consistent with that in the clinical study.
Publisher
Russian Society of Clinical Oncology
Subject
General Agricultural and Biological Sciences
Reference31 articles.
1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68 (6):394–424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
2. Izmailov A. A., Ayupov R. T., Sulatnbaev A. V., Musin Sh. I., Men'shikov K. V., Zabelin M. V. Organizatsiya raboty onkologicheskoi sluzhby v Respublike Bashkortostan v usloviyakh pandemii COVID-19. Sovremennye problemy zdravookhraneniya i meditsinskoi statistiki 2020 g., № 3. C. 195-208. DOI: 10.24411/2312-2935-2020-00067.
3. Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2021 godu. Pod redaktsiei Kaprina A. D., Starinskogo V. V., Shakhazadovoi A. O.: MNIOI im. P. A. Gertsena – filial FGBU «NMITs radiologii» Minzdrava Rossii, 2021. 239 s. ISBN 978-5-85502-262-9.
4. Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med 2017;376:354-66.
5. McKay RR, Bosse D, Choueiri TK. Evolving systemic treatment landscape for patients with advanced renal cell carcinoma. J Clin Oncol 2018 October 29 (Epub ahead of print).